The Babraham Institute aims to maximise the impact of its scientific discoveries; where appropriate this is achieved through commercialisation of its intellectual property rights. This primarily involves licensing new discoveries and technologies to pharma and biotech companies, but in some cases commercialisation is achieved through spinning out new companies (for example Crescendo Biologics Ltd).
Current opportunities for licensing the Babraham Institute’s intellectual property include:
Enhancing the potency of stem cells Download flier
International patent applications filed in USA, Europe, Japan, Australia, Canada, China. (priority date 17th December 2012) Worldwide
VDJ-Seq Download flier
International patent applications filed in Europe, USA and Japan (priority date 2nd March 2012) Non-exclusive, worldwide
Capture Hi-C: Deciphering the 3D folding of the genome
Please contact us for further details.
Priority patent application filed 5th September 2013. Worldwide
Crescendo Biologics Ltd
was spun out of the Babraham Institute in 2008. The company is focussed on developing a transgenic mouse platform for the in vivo generation of human, high-affinity, soluble, VH antibody fragments, the smallest fragments that retain antibody binding and have many desirable properties as potential therapeutics. In 2010 the company announced the generation of the first “triple-knockout” mouse, and in late 2013 it received £19.5M Series A funding. Crescendo Biologics is based on the Babraham Research Campus, and continues to collaborate with Institute scientists.
Monoclonal Antibody against 5-hmC
A reagent specific for 5-hydroxymethylcytosine (5-hmC) was developed by Babraham’s monoclonal antibody laboratory in collaboration with Professor Adrian Bird at the University of Edinburgh and Professor Wolf Reik’s group
at Babraham. 5-hmC is a novel type of epigenetic modification enriched in euchromatic areas of the genome and associated with increased gene expression.
The monoclonal antibody developed has proved of value for assays of this epigenetic mark and has now been licensed non-exclusively to several companies.
Please contact us if you are interested in licensing Babraham Institute discoveries.
Dr Katy Montague, Commercialisation Manager
+44 (0)1223 496208